Genetic and cellular modifiers of oxidative stress: What can we learn from fatty acid oxidation defects?

Molecular Genetics and Metabolism

Volumn 110, Issue SUPPL., 2013, Pages

  Olsen, Rikke Katrine Jentoft ^a   Cornelius, Nanna ^a   Gregersen, Niels ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cofactors; Fatty acid oxidation; Mitochondria; Oxidative stress; Reactive oxygen species

Indexed keywords

BUTYRIC ACID; FATTY ACID; FLAVINE ADENINE NUCLEOTIDE; HYDROGEN PEROXIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MANGANESE SUPEROXIDE DISMUTASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; UBIDECARENONE;

CELL DEATH; CELL METABOLISM; CELL PROTECTION; CELL STRESS; CELL SURVIVAL; CELLULAR STRESS RESPONSE; ENERGY YIELD; FATTY ACID OXIDATION; GENETIC VARIABILITY; GLYCOLYSIS; HEAT SHOCK RESPONSE; INDEL MUTATION; METABOLIC REGULATION; MISSENSE MUTATION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PREMATURE TERMINATION CODON; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTON MOTIVE FORCE; REGULATORY MECHANISM; RESPIRATORY CHAIN; REVIEW; SIGNAL TRANSDUCTION; STOP CODON;

ACAD; ACYL-COA DEHYDROGENASE; COFACTORS; FAO; FATTY ACID OXIDATION; LCHAD; LONG-CHAIN 3-HYDROXY ACYL-COA DEHYDROGENASE; MADD; MCAD; MEDIUM-CHAIN ACYL-COA DEHYDROGENASE; MITOCHONDRIA; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN; MTP; MULTIPLE ACYL-COA DEHYDROGENASE DEFICIENCY; OXIDATIVE STRESS; PAH; PHENYLALANINE HYDROXYLASE; PHENYLKETONURI; PKU; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; RNS; ROS; SCAD; SHORT-CHAIN ACYL-COA DEHYDROGENASE; VERY-LONG-CHAIN ACYL-COA DEHYDROGENASE; VLCAD;

ANTIOXIDANTS; APOPTOSIS; BEZAFIBRATE; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; FATTY ACIDS; GENETIC VARIATION; GENOTYPE; HUMANS; LIPID METABOLISM, INBORN ERRORS; NECROSIS; OXIDATIVE STRESS; PHENOTYPE; PROTEIN FOLDING; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES;

EID: 84889580379     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2013.10.007     Document Type: Review

References (87)

1. Andresen B.S., Olpin S., Poorthuis B.J., Scholte H.R., Vianey-Saban C., Wanders R., Ijlst L., Morris A., Pourfarzam M., Bartlett K., Baumgartner E.R., Deklerk J.B., Schroeder L.D., Corydon T.J., Lund H., Winter V., Bross P., Bolund L., Gregersen N. Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am. J. Hum. Genet. 1999, 64:479-494.
2. Olsen R.K., Andresen B.S., Christensen E., Bross P., Skovby F., Gregersen N. Clear relationship between ETF/ETFDH genotype and phenotype in patients with multiple acyl-CoA dehydrogenation deficiency. Hum. Mutat. 2003, 22:12-23.
3. Gregersen N., Andresen B.S., Corydon M.J., Corydon T.J., Olsen R.K., Bolund L., Bross P. Mutation analysis in mitochondrial fatty acid oxidation defects: exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship. Hum. Mutat. 2001, 18:169-189.
4. Gregersen N., Bross P., Andresen B.S. Genetic defects in fatty acid beta-oxidation and acyl-CoA dehydrogenases. Molecular pathogenesis and genotype-phenotype relationships. Eur. J. Biochem. 2004, 271:470-482.
5. Arnold G.L., Saavedra-Matiz C.A., Galvin-Parton P.A., Erbe R., Devincentis E., Kronn D., Mofidi S., Wasserstein M., Pellegrino J.E., Levy P.A., Adams D.J., Nichols M., Caggana M. Lack of genotype-phenotype correlations and outcome in MCAD deficiency diagnosed by newborn screening in New York State. Mol. Genet. Metab. 2010, 99:263-268.
6. Gregersen N., Andresen B.S., Pedersen C.B., Olsen R.K., Corydon T.J., Bross P. Mitochondrial fatty acid oxidation defects-remaining challenges. J. Inherit. Metab. Dis. 2008, 31:643-657.
7. Rebbapragada I., Lykke-Andersen J. Execution of nonsense-mediated mRNA decay: what defines a substrate?. Curr. Opin. Cell Biol. 2009, 21:394-402.
8. Gregersen N., Bross P., Vang S., Christensen J.H. Protein misfolding and human disease. Annu. Rev. Genomics Hum. Genet. 2006, 7:103-124.
9. Kikis E.A., Gidalevitz T., Morimoto R.I. Protein homeostasis in models of aging and age-related conformational disease. Adv. Exp. Med. Biol. 2010, 694:138-159.
10. Dahl D.R., Dahl N., Samson F.E. A study on the narcotic action of the short chain fatty acids. J. Clin. Invest. 1956, 1291-1298.
11. Hird F.J., Weidemann M.J. Oxidative phosphorylation accompanying oxidation of short-chain fatty acids by rat-liver mitochondria. Biochem. J. 1966, 98:378-388.
12. Gregersen N. Studies on the effects of saturated and unsaturated short-chain monocarboxylic acids on the energy metabolism of rat liver mitochondria. Pediatr. Res. 1979, 13:1227-1230.
13. Tonin A.M., Ferreira G.C., Grings M., Viegas C.M., Busanello E.N., Amaral A.U., Zanatta A., Schuck P.F., Wajner M. Disturbance of mitochondrial energy homeostasis caused by the metabolites accumulating in LCHAD and MTP deficiencies in rat brain. Life Sci. 2010, 86:825-831.
14. Tonin A.M., Amaral A.U., Busanello E.N., Grings M., Castilho R.F., Wajner M. Long-chain 3-hydroxy fatty acids accumulating in long-chain 3-hydroxyacyl-CoA dehydrogenase and mitochondrial trifunctional protein deficiencies uncouple oxidative phosphorylation in heart mitochondria. J. Bioenerg. Biomembr. 2013, 45:47-57.
15. Schuck P.F., Ceolato P.C., Ferreira G.C., Tonin A., Leipnitz G., Dutra-Filho C.S., Latini A., Wajner M. Oxidative stress induction by cis-4-decenoic acid: relevance for MCAD deficiency. Free Radic. Res. 2007, 41:1261-1272.
16. Scaini G., Simon K.R., Tonin A.M., Busanello E.N., Moura A.P., Ferreira G.C., Wajner M., Streck E.L., Schuck P.F. Toxicity of octanoate and decanoate in rat peripheral tissues: evidence of bioenergetic dysfunction and oxidative damage induction in liver and skeletal muscle. Mol. Cell. Biochem. 2012, 361:329-335.
17. Sauer S.W., Okun J.G., Hoffmann G.F., Koelker S., Morath M.A. Impact of short- and medium-chain organic acids, acylcarnitines, and acyl-CoAs on mitochondrial energy metabolism. Biochim. Biophys. Acta 2008, 1777:1276-1282.
18. Wakabayashi M., Kamijo Y., Nakajima T., Tanaka N., Sugiyama E., Yangyang T., Kimura T., Aoyama T. Fatty acid accumulation and resulting PPARalpha activation in fibroblasts due to trifunctional protein deficiency. PPAR Res. 2012, 2012:371691.
19. Davie J.R. Inhibition of histone deacetylase activity by butyrate. J. Nutr. 2003, 133:2485S-2493S.
20. Pedersen C.B., Kolvraa S., Kolvraa A., Stenbroen V., Kjeldsen M., Ensenauer R., Tein I., Matern D., Rinaldo P., Vianey-Saban C., Ribes A., Lehnert W., Christensen E., Corydon T.J., Andresen B.S., Vang S., Bolund L., Vockley J., Bross P., Gregersen N. The ACADS gene variation spectrum in 114 patients with short-chain acyl-CoA dehydrogenase (SCAD) deficiency is dominated by missense variations leading to protein misfolding at the cellular level. Hum. Genet. 2008, 124:43-56.
21. Schuck P.F., Busanello E.N., Moura A.P., Tonin A.M., Grings M., Ritter L., Vargas C.R., Da Costa F.G., Wajner M. Promotion of lipid and protein oxidative damage in rat brain by ethylmalonic acid. Neurochem. Res. 2010, 35:298-305.
22. Ferreira G.C., Andre K.R., Schuck P.F., Viegas C.M., Tonin A., Coelho D.M., Wyse A.T., Wannmacher C.M., Vargas C.R., Wajner M. Effect of in vivo administration of ethylmalonic acid on energy metabolism in rat tissues. Metab. Brain Dis. 2006, 21:29-39.
23. Seppet E., Gruno M., Peetsalu A., Gizatullina Z., Nguyen H.P., Vielhaber S., Wussling M.H., Trumbeckaite S., Arandarcikaite O., Jerzembeck D., Sonnabend M., Jegorov K., Zierz S., Striggow F., Gellerich F.N. Mitochondria and energetic depression in cell pathophysiology. Int. J. Mol. Sci. 2009, 10:2252-2303.
24. Marcovina S.M., Sirtori C., Peracino A., Gheorghiade M., Borum P., Remuzzi G., Ardehali H. Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of l-carnitine. Transl. Res. 2013, 161:73-84.
25. Schmidt S.P., Corydon T.J., Pedersen C.B., Bross P., Gregersen N. Misfolding of short-chain acyl-CoA dehydrogenase leads to mitochondrial fission and oxidative stress. Mol. Genet. Metab. 2010, 100:155-162.
26. Pedersen C.B., Zolkipli Z., Vang S., Palmfeldt J., Kjeldsen M., Stenbroen V., Schmidt S.P., Wanders R.J., Ruiter J.P., Wibrand F., Tein I., Gregersen N. Antioxidant dysfunction: potential risk for neurotoxicity in ethylmalonic aciduria. J. Inherit. Metab. Dis. 2010, 33:211-222.
27. Zolkipli Z., Pedersen C.B., Lamhonwah A.M., Gregersen N., Tein I. Vulnerability to oxidative stress in vitro in pathophysiology of mitochondrial short-chain acyl-CoA dehydrogenase deficiency: response to antioxidants. PLoS One 2011, 6:e17534.
28. Cornelius N., Frerman F.E., Corydon T.J., Palmfeldt J., Bross P., Gregersen N., Olsen R.K. Molecular mechanisms of riboflavin responsiveness in patients with ETF-QO variations and multiple acyl-CoA dehydrogenation deficiency. Hum. Mol. Genet. 2012, 21:3435-3448.
29. Ribas G.S., Sitta A., Wajner M., Vargas C.R. Oxidative stress in phenylketonuria: what is the evidence?. Cell. Mol. Neurobiol. 2011, 31:653-662.
30. Rocha J.C., Martins M.J. Oxidative stress in phenylketonuria: future directions. J. Inherit. Metab. Dis. 2012, 35:381-398.
31. Murphy M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2009, 417:1-13.
32. Drose S., Brandt U. Molecular mechanisms of superoxide production by the mitochondrial respiratory chain. Adv. Exp. Med. Biol. 2012, 748:145-169.
33. St-Pierre J., Buckingham J.A., Roebuck S.J., Brand M.D. Topology of superoxide production from different sites in the mitochondrial electron transport chain. J. Biol. Chem. 2002, 277:44784-44790.
34. Schrauwen P., Schrauwen-Hinderling V., Hoeks J., Hesselink M.K. Mitochondrial dysfunction and lipotoxicity. Biochim. Biophys. Acta 2010, 1801:266-271.
35. Maranzana E., Barbero G., Falasca A.I., Lenaz G., Genova M.L. Mitochondrial respiratory supercomplex association limits production of reactive oxygen species from complex I. Antioxid. Redox Signal. 2013, 19:1469-1480.
36. Gregersen N., Bross P. Protein misfolding and cellular stress: an overview. Methods Mol. Biol. 2010, 648:3-23.
37. Sena L.A., Chandel N.S. Physiological roles of mitochondrial reactive oxygen species. Mol. Cell 2012, 48:158-167.
38. Cai Z., Yan L.J. Protein oxidative modifications: beneficial roles in disease and health. J. Biochem. Pharmacol. Res. 2013, 1:15-26.
39. Fischer F., Hamann A., Osiewacz H.D. Mitochondrial quality control: an integrated network of pathways. Trends Biochem. Sci. 2012, 37:284-292.
40. Martindale J.L., Holbrook N.J. Cellular response to oxidative stress: signaling for suicide and survival. J. Cell. Physiol. 2002, 192:1-15.
41. Ray P.D., Huang B.W., Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell. Signal. 2012, 24:981-990.
42. Held J.M., Gibson B.W. Regulatory control or oxidative damage? Proteomic approaches to interrogate the role of cysteine oxidation status in biological processes. Mol. Cell. Proteomics 2012, 11:R111.
43. Jacobs A.T., Marnett L.J. Systems analysis of protein modification and cellular responses induced by electrophile stress. Acc. Chem. Res. 2010, 43:673-683.
44. Forman H.J., Davies K.J., Ursini F. How do nutritional antioxidants really work: nucleophilic tone and para-hormesis versus free radical scavenging in vivo. Free Radic. Biol. Med. 2013, (Electronic publication ahead of print).
45. Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. Toxicol. 2013, 53:401-426.
46. Tian H., Zhang B., Di J., Jiang G., Chen F., Li H., Li L., Pei D., Zheng J. Keap1: one stone kills three birds Nrf2, IKKbeta and Bcl-2/Bcl-xL. Cancer Lett. 2012, 325:26-34.
47. Kant R., Bali A., Singh N., Jaggi A.S. Prolyl 4 hydroxylase: a critical target in the pathophysiology of diseases. Korean J. Physiol. Pharmacol. 2013, 17:111-120.
48. Yuan H.X., Xiong Y., Guan K.L. Nutrient sensing, metabolism, and cell growth control. Mol. Cell 2013, 49:379-387.
49. Hagen T. Oxygen versus reactive oxygen in the regulation of HIF-1alpha: the balance tips. Biochem. Res. Int. 2012, 2012:436981.
50. Page E.L., Chan D.A., Giaccia A.J., Levine M., Richard D.E. Hypoxia-inducible factor-1alpha stabilization in nonhypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol. Biol. Cell 2008, 19:86-94.
51. Finkel T. Signal transduction by mitochondrial oxidants. J. Biol. Chem. 2012, 287:4434-4440.
52. Huang C., Han Y., Wang Y., Sun X., Yan S., Yeh E.T., Chen Y., Cang H., Li H., Shi G., Cheng J., Tang X., Yi J. SENP3 is responsible for HIF-1 transactivation under mild oxidative stress via p300 de-SUMOylation. EMBO J. 2009, 28:2748-2762.
53. Wang Y., Yang J., Yang K., Cang H., Huang X.Z., Li H., Yi J. The biphasic redox sensing of SENP3 accounts for the HIF-1 transcriptional activity shift by oxidative stress. Acta Pharmacol. Sin. 2012, 33:953-963.
54. Schuck P.F., Ferreira G.C., Tonin A.M., Viegas C.M., Busanello E.N., Moura A.P., Zanatta A., Klamt F., Wajner M. Evidence that the major metabolites accumulating in medium-chain acyl-CoA dehydrogenase deficiency disturb mitochondrial energy homeostasis in rat brain. Brain Res. 2009, 1296:117-126.
55. Lopez-Erauskin J., Galino J., Ruiz M., Cuezva J.M., Fabregat I., Cacabelos D., Boada J., Martinez J., Ferrer I., Pamplona R., Villarroya F., Portero-Otin M., Fourcade S., Pujol A. Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy. Hum. Mol. Genet. 2013, 22:3296-3305.
56. Bobba A., Amadoro G., Valenti D., Corsetti V., Lassandro R., Atlante A. Mitochondrial respiratory chain Complexes I and IV are impaired by beta-amyloid via direct interaction and through Complex I-dependent ROS production, respectively. Mitochondrion 2013, 13:298-311.
57. Cornelius N., Byron C., Hargreaves I., Guerra P.F., Furdek A.K., Land J., Radford W.W., Frerman F., Corydon T.J., Gregersen N., Olsen R.K. Secondary coenzyme Q10 deficiency and oxidative stress in cultured fibroblasts from patients with riboflavin responsive multiple Acyl-CoA dehydrogenation deficiency. Hum. Mol. Genet. 2013, 22:3819-3827.
58. Gempel K., Topaloglu H., Talim B., Schneiderat P., Schoser B.G., Hans V.H., Palmafy B., Kale G., Tokatli A., Quinzii C., Hirano M., Naini A., Dimauro S., Prokisch H., Lochmuller H., Horvath R. The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain 2007, 130:2037-2044.
59. Wolfe L.A., He M., Vockley J., Payne N., Rhead W., Hoppel C., Spector E., Gernert K., Gibson K.M. Novel ETF dehydrogenase mutations in a patient with mild glutaric aciduria type II and complex II-III deficiency in liver and muscle. J. Inherit. Metab. Dis. 2010, 33(Suppl. 3):481-487.
60. Wen B., Dai T., Li W., Zhao Y., Liu S., Zhang C., Li H., Wu J., Li D., Yan C. Riboflavin-responsive lipid-storage myopathy caused by ETFDH gene mutations. J. Neurol. Neurosurg. Psychiatry 2010, 81:231-236.
61. Rocha H., Ferreira R., Carvalho J., Vitorino R., Santa C., Lopes L., Gregersen N., Vilarinho L., Amado F. Characterization of mitochondrial proteome in a severe case of ETF-QO deficiency. J. Proteomics 2011, 75:221-228.
62. Song Y., Selak M.A., Watson C.T., Coutts C., Scherer P.C., Panzer J.A., Gibbs S., Scott M.O., Willer G., Gregg R.G., Ali D.W., Bennett M.J., Balice-Gordon R.J. Mechanisms underlying metabolic and neural defects in zebrafish and human multiple acyl-CoA dehydrogenase deficiency (MADD). PLoS One 2009, 4:e8329.
63. Kim S.H., Scott S.A., Bennett M.J., Carson R.P., Fessel J., Brown H.A., Ess K.C. Multi-organ abnormalities and mTORC1 activation in zebrafish model of multiple acyl-CoA dehydrogenase deficiency. PLoS Genet. 2013, 9:e1003563.
64. Naviaux R.K. Oxidative shielding or oxidative stress?. J. Pharmacol. Exp. Ther. 2012, 342:608-618.
65. Henriques B.J., Olsen R.K., Bross P., Gomes C.M. Emerging roles for riboflavin in functional rescue of mitochondrial beta-oxidation flavoenzymes. Curr. Med. Chem. 2010, 17:3842-3854.
66. Yonezawa A., Inui K. Novel riboflavin transporter family RFVT/SLC52: identification, nomenclature, functional characterization and genetic diseases of RFVT/SLC52. Mol. Aspects Med. 2013, 34:693-701.
67. Rahman S., Clarke C.F., Hirano M. 176th ENMC international workshop: diagnosis and treatment of coenzyme Q(1)(0) deficiency. Neuromuscul. Disord. 2012, 22:76-86.
68. Saijo T., Tanaka K. Isoalloxazine ring of FAD is required for the formation of the core in the Hsp60-assisted folding of medium chain acyl-CoA dehydrogenase subunit into the assembly competent conformation in mitochondria. J. Biol. Chem. 1995, 270:1899-1907.
69. Nagao M., Tanaka K. FAD-dependent regulation of transcription, translation, post-translational processing, and post-processing stability of various mitochondrial acyl-CoA dehydrogenases and of electron transfer flavoprotein and the site of holoenzyme formation. J. Biol. Chem. 1992, 267:17925-17932.
70. Sato K., Nishina Y., Shiga K. Preparation of separated alpha and beta subunits of electron-transferring flavoprotein in unfolded forms and their restoration to the native holoprotein form. J. Biochem. 1994, 116:147-155.
71. Lucas T.G., Henriques B.J., Rodrigues J.V., Bross P., Gregersen N., Gomes C.M. Cofactors and metabolites as potential stabilizers of mitochondrial acyl-CoA dehydrogenases. Biochim. Biophys. Acta 2011, 1812:1658-1663.
72. Henriques B.J., Rodrigues J.V., Olsen R.K., Bross P., Gomes C.M. Role of flavinylation in a mild variant of multiple acyl-CoA dehydrogenation deficiency: a molecular rationale for the effects of riboflavin supplementation. J. Biol. Chem. 2009, 284:4222-4229.
73. Henriques B.J., Bross P., Gomes C.M. Mutational hotspots in electron transfer flavoprotein underlie defective folding and function in multiple acyl-CoA dehydrogenase deficiency. Biochim. Biophys. Acta 2010, 1802:1070-1077.
74. Gregersen N. Riboflavin-responsive defects of beta-oxidation. J. Inherit. Metab. Dis. 1985, 8(Suppl. 1):65-69.
75. Bosch A.M., Stroek K., Abeling N.G., Waterham H.R., Ijlst L., Wanders R.J. The Brown-Vialetto-Van Laere and Fazio Londe syndrome revisited: natural history, genetics, treatment and future perspectives. Orphanet J. Rare Dis. 2012, 7:83.
76. Horvath R. Update on clinical aspects and treatment of selected vitamin-responsive disorders II (riboflavin and CoQ 10). J. Inherit. Metab. Dis. 2012, 35:679-687.
77. Ho G., Yonezawa A., Masuda S., Inui K., Sim K.G., Carpenter K., Olsen R.K., Mitchell J.J., Rhead W.J., Peters G., Christodoulou J. Maternal riboflavin deficiency, resulting in transient neonatal-onset glutaric aciduria Type 2, is caused by a microdeletion in the riboflavin transporter gene GPR172B. Hum. Mutat. 2011, 32:E1976-E1984.
78. Bosch A.M., Abeling N.G., Ijlst L., Knoester H., Van Der Pol W.L., Stroomer A.E., Wanders R.J., Visser G., Wijburg F.A., Duran M., Waterham H.R. Brown-Vialetto-Van Laere and Fazio Londe syndrome is associated with a riboflavin transporter defect mimicking mild MADD: a new inborn error of metabolism with potential treatment. J. Inherit. Metab. Dis. 2011, 34:159-164.
79. Bujan N., Arias A., Montero R., Garcia-Villoria J., Lissens W., Seneca S., Espinos C., Navas P., De M.L., Artuch R., Briones P., Ribes A. Characterization of CoQ biosynthesis in fibroblasts of patients with primary and secondary CoQ deficiency. J. Inherit. Metab. Dis. 2013, (Electronic publication ahead of print).
80. Yen H.C., Chen F.Y., Chen S.W., Huang Y.H., Chen Y.R., Chen C.W. Effect of mitochondrial dysfunction and oxidative stress on endogenous levels of coenzyme Q(10) in human cells. J. Biochem. Mol. Toxicol. 2011, 25:280-289.
81. Kaochar S., Tu B.P. Gatekeepers of chromatin: small metabolites elicit big changes in gene expression. Trends Biochem. Sci. 2012, 37:477-483.
82. Lee S.K., Lee J.O., Kim J.H., Kim N., You G.Y., Moon J.W., Sha J., Kim S.J., Lee Y.W., Kang H.J., Park S.H., Kim H.S. Coenzyme Q10 increases the fatty acid oxidation through AMPK-mediated PPARalpha induction in 3T3-L1 preadipocytes. Cell. Signal. 2012, 24:2329-2336.
83. Gobin-Limballe S., Djouadi F., Aubey F., Olpin S., Andresen B.S., Yamaguchi S., Mandel H., Fukao T., Ruiter J.P., Wanders R.J., McAndrew R., Kim J.J., Bastin J. Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy. Am. J. Hum. Genet. 2007, 81:1133-1143.
84. Bonnefont J.P., Bastin J., Behin A., Djouadi F. Bezafibrate for an inborn mitochondrial beta-oxidation defect. N. Engl. J. Med. 2009, 360:838-840.
85. Bonnefont J.P., Bastin J., Laforet P., Aubey F., Mogenet A., Romano S., Ricquier D., Gobin-Limballe S., Vassault A., Behin A., Eymard B., Bresson J.L., Djouadi F. Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency. Clin. Pharmacol. Ther. 2010, 88:101-108.
86. Yamaguchi S., Li H., Purevsuren J., Yamada K., Furui M., Takahashi T., Mushimoto Y., Kobayashi H., Hasegawa Y., Taketani T., Fukao T., Fukuda S. Bezafibrate can be a new treatment option for mitochondrial fatty acid oxidation disorders: evaluation by in vitro probe acylcarnitine assay. Mol. Genet. Metab. 2012, 107:87-91.
87. Koene S., Smeitink J. Mitochondrial medicine. J. Inherit. Metab. Dis. 2011, 34:247-248.